F901318 - A Phase I, Double-Blind, Placebo Controlled, Single Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects
Phase of Trial: Phase I
Latest Information Update: 21 Sep 2015
Price : $35 *
At a glance
- Drugs Olorofim (Primary)
- Indications Aspergillosis
- Focus Adverse reactions; First in man
- Sponsors F2G
- 21 Sep 2015 Results assessing pharmacokinetics presented at the Joint 55th Interscience Conference on Antimicrobial Agents and Chemotherapy and 28th International Congress of Chemotherapy
- 10 Nov 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 14 Aug 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.